Natural Killer (NK) cells are gaining attention in the scientific community as a potential factor in understanding neurodegenerative diseases like Alzheimer’s, Parkinson’s, ALS, and multiple sclerosis. Despite the growing interest, researchers caution that the evidence supporting NK cell therapy as a treatment for these conditions is still in its infancy. NK cells, integral to the innate immune system, are known for identifying and responding to infected or abnormal cells, and their role in influencing inflammatory responses is a subject of active research.
Recent studies are delving into the connection between immune activity and neurodegeneration, particularly in diseases characterized by chronic inflammation and abnormal protein accumulation. A Phase I clinical trial conducted in 2025 investigated the use of expanded NK cells in Alzheimer’s patients. This study involved 11 participants receiving intravenous infusions of an autologous, non-genetically modified expanded NK cell product. While the primary goal was to assess safety, some changes in cognitive measures and biomarkers, such as pTau181 and GFAP, were observed. However, the study’s small scale was not sufficient to determine the therapy’s effectiveness in preventing or slowing down Alzheimer’s, necessitating larger trials for conclusive results.
In Parkinson’s disease research, preclinical findings have shown that NK cells can interact with and degrade alpha-synuclein aggregates in lab and animal models. A 2020 study highlighted that depleting NK cells in mice increased alpha-synuclein pathology and neuroinflammation, suggesting a regulatory role in immune activity related to Parkinson’s. Nonetheless, this evidence remains largely preclinical, and the potential of NK cell therapy to treat Parkinson’s in humans is yet to be established.
The complexity of NK cells’ involvement in neurological diseases is evident, as different NK cell populations exhibit varied functions based on disease type and stage. Simply increasing NK cell numbers might not yield beneficial outcomes, prompting researchers to explore which cell populations, activation states, doses, and schedules may prove useful. Critical questions remain about the cells’ effectiveness in influencing the central nervous system, their duration of activity, and their impact on long-term disease progression.
Currently, NK cell therapy is an investigational area in cellular medicine, with ongoing research yet to establish its safety and effectiveness conclusively. Individuals considering such therapies are advised to consult qualified healthcare professionals and thoroughly evaluate the scientific evidence, safety, and regulatory status. The R3 Life Wellness Center emphasizes that NK cell therapy for neurodegenerative diseases remains experimental and should not be considered an established treatment. This article is intended for educational purposes only and does not serve as medical advice.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.